Primary Site >> Biliary tract Cancer
Gene >> MTOR
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Identification of novel cellular targets in biliary tract cancers using global gene expression technology. PMID: 12819026 |
Ref: Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. PMID: 16767220 |
Ref: Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model. PMID: 17440093 |
Ref: The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma. PMID: 19147772 Ref: Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells. PMID: 19509244 |
Ref: Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma. PMID: 21492330 |
Ref: The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas. PMID: 21874010 Ref: Immunohistochemical analysis of the mTOR pathway in intrahepatic cholangiocarcinoma. PMID: 22248270 Ref: Cancer of the ampulla of Vater: analysis of the whole genome sequence exposes a potential therapeutic vulnerability. PMID: 22762308 |
Ref: Rapamycin inhibits both motility through down-regulation of p-STAT3 (S727) by disrupting the mTORC2 assembly and peritoneal dissemination in sarcomatoid cholangiocarcinoma. PMID: 22875246 Ref: The mTOR pathway in hepatic malignancies. PMID: 23408390 Ref: Immunohistochemical expression of phospho-mTOR is associated with poor prognosis in patients with gallbladder adenocarcinoma. PMID: 23544944 Ref: Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma. PMID: 23588885 Ref: Antiproliferative and apoptosis-inducing activity of curcumin against human gallbladder adenocarcinoma cells. PMID: 23645731 Ref: Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy. PMID: 23832540 Ref: AKT/mTOR substrate P70S6K is frequently phosphorylated in gallbladder cancer tissue and cell lines. PMID: 24124380 |
Ref: Inhibition of mTOR pathway attenuates migration and invasion of gallbladder cancer via EMT inhibition. PMID: 24623408 Ref: Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines. PMID: 24788596 Ref: Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma. PMID: 24796583 Ref: Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study. PMID: 24827133 Ref: Phenoxodiol enhances the antitumor activity of gemcitabine in gallbladder cancer through suppressing Akt/mTOR pathway. PMID: 24902539 Ref: Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors. PMID: 25152244 Ref: Cholangiocarcinoma: molecular pathways and therapeutic opportunities. PMID: 25369307 Ref: Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PMID: 25536104 |
Ref: Targeting specific molecular pathways holds promise for advanced gallbladder cancer therapy. PMID: 25639632 Ref: Fibronectin promotes cell proliferation and invasion through mTOR signaling pathway activation in gallbladder cancer. PMID: 25657110 Ref: Loss of angiotensin-converting enzyme 2 promotes growth of gallbladder cancer. PMID: 25663464 Ref: Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer. PMID: 25742482 Ref: FBXW7 suppresses epithelial-mesenchymal transition, stemness and metastatic potential of cholangiocarcinoma cells. PMID: 25749036 Ref: Expression of insulin-like growth factor I receptor as a biomarker for predicting prognosis in biliary tract cancer patients. PMID: 26137252 Ref: Histone Deacetylase Inhibitors Inhibit the Proliferation of Gallbladder Carcinoma Cells by Suppressing AKT/mTOR Signaling. PMID: 26287365 Ref: Inactivation of tumor suppressor gene pten in early and advanced gallbladder cancer. PMID: 26294099 Ref: Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in mice. PMID: 26397134 Ref: Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures. PMID: 26571380 |
Ref: A potent therapeutics for gallbladder cancer by combinatorial inhibition of the MAPK and mTOR signaling networks. PMID: 26614007 Ref: Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice. PMID: 26877611 Ref: Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma. PMID: 26967384 Ref: Inhibition of mTOR suppresses human gallbladder carcinoma cell proliferation and enhances the cytotoxicity of 5-fluorouracil by downregulating MDR1 expression. PMID: 27212159 Ref: Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans. PMID: 27918553 |
Ref: Guidance to rational use of pharmaceuticals in gallbladder sarcomatoid carcinoma using patient-derived cancer cells and whole exome sequencing. PMID: 28029662 Ref: SNORA74B gene silencing inhibits gallbladder cancer cells by inducing PHLPP and suppressing Akt/mTOR signaling. PMID: 28212545 Ref: K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines. PMID: 28544747 Ref: Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a PIK3CA mutation. PMID: 28694672 Ref: Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice. PMID: 28733220 Ref: LncRNA-PAGBC acts as a microRNA sponge and promotes gallbladder tumorigenesis. PMID: 28887321 |
Ref: PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay. PMID: 29474549 Ref: Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study. PMID: 29527009 Ref: Combined CDK4/6 and pan-mTOR inhibition is synergistic against intrahepatic cholangiocarcinoma. PMID: 30084835 |